FORMULATION APPROACHES FOR SUSTAINED RELEASE DOSAGE FORMS: A REVIEW

  • Sudhir Karna
  • Shashank Chaturvedi
  • Vipin Agrawal
  • Mohammad Alim

Abstract

Over the past 30 years, as the expense and complications involved in marketing new drug entities have increased, with concomitant recognition of
the therapeutic advantages of controlled drug delivery, greater attention has been focused on development of sustained or controlled release drug
delivery systems (DDS). For many disease states, a substantial number of therapeutically effective compounds already exist. The effectiveness of these
drugs is often limited by side effects or necessity to administer the compound in an ethical setting. The goal in designing sustained drug delivery
is to reduce the frequency of dosing or to increase the effectiveness of the drug by localization at the site of action, reducing the dose required or
providing uniform drug delivery. The design of oral sustained release DDS depends on various factors such as, physicochemical properties of drug,
type of delivery system, disease being treated, and patient condition, and treatment duration, presence of food, gastrointestinal motility, and coadministration
of other drugs.
Keywords: Sustained release drug delivery system, Dose frequency, Biological half-life, Physicochemical properties of drugs.

References

. Chein YW. Novel Drug Delivery System. Revised and Expanded.
2
ed. New York: Marcel Dekker; 2005.
2. Vamsy KA, Srinath KR, Chowdary PC. Formulation development
nd
b
a
Fig. 6: Schematic illustration of drug release from osmosis sustaining system
and evaluation of divalproex sodium extended release tablet. Int J Res
Pharm Biomed Sci 2011;2:809-32.
3. Jivraj I I, Martini LG, Thomson CM. An overview of the different
excipients useful for the direct compression of tablets. Pharm Sci
Technolo Today 2000;3(2):58-63.
4. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advance.
New Delhi: Vallabh Prakashan; 2002. p. 155-95.
3
.
5. Longer MA, Robinson JR. Sustained release drug delivery system. In:
Remington JP, editor. The Science and Practice of Pharmacy. 18
ed.
Philadelphia: The Philadelphia College of Pharmacy and Science;
1990. p. 1677-9.
6. Wani MS, Controlled release system-A. Rev 2008;6(1): www.
pharmainfo.net/review. Available from: http://www.pharmainfo.net/
reviews/controlled-released-system-review.
7. Bechgaard H, Nielson GH. Controlled release multiple units and single
unit dosage. Drug Dev Ind Pharm 1978;4(1):53-67.
8. Bhowmik D, Kumar KP, Dutta A, Paswan S. Trends in scope and
opportunities of control release oral drug delivery systems. Crit Rev
Pharm Sci 2012;1:20-33.
9. Patel H, Panchal DR, Patel U, Brahmbhatt T. Matrix type drug delivery
system: A review. J Pharm Sci Biosci Res 2011;1(3):143-51.
10. Dixit N, Maurya SD, Bhanu PS. Sustained release drug delivery system.
Indian J Res Pharm Biotechnol 2013;1:305-10.
11. Kola R, Kumar BP. A detailed description of synthetic and natural
polymers which are used in the formulation of sustained release drug
delivery system: A review. J Chem Pharm Sci 2013;6:161-9.
12. Ratnaparkhi MP, Gupta JP. Sustained release oral drug delivery system
– An overview. Int J Pharm Res Rev 2013;2:11-21.
13. Pundir S, Badola A, Sharma D. Sustained release matrix technology
and recent advance in matrix drug delivery system: A review. Int J Drug
Res Tech 2013;3:12-20.
14. Amabile CM, Bowman BJ. Overview of oral modified-release opioid
products for the management of chronic pain. Ann Pharmacother
2006;40(7-8):1327-35.
15. Efentakis M, Peponaki C. Formulation study and evaluation of
matrix and three-layer tablet sustained drug delivery systems based
on Carbopols with isosorbite mononitrate. AAPS PharmSciTech
2008;9(3):917-23.
16. Available from: http://www.rxlist.com/k-tab-drug.htm.
17. Nanjwade BK, Mhase SR, Manvi FV. Formulation of extended release
of metformin HCl matrix tablet. Trop J Pharm Res 2011;10(4):375-83.
18. Packiaraj JM, Vankateswaran CS, Janakiraman K. Formulation
and evaluation of extended release matrix tablet of clarithromycin
using fluid bed granulation process. Int J Res Pharm Biomed Sci
2013;4:1318-32.
19. Gupta BP, Thakur N, Jain NP, Banweer J, Jain S. Osmotically
controlled drug delivery system with associated drugs. J Pharm Pharm
Sci 2010;13(4):571-88.
th
40
Asian J Pharm Clin Res, Vol 8, Issue 5, 2015, 34-41
Karna et al.
20. Patel RR, Patel JK. Novel technologies of controlled release drug
delivery systems. Syst Rev Pharm 2010;1(2):128-32.
21. Panikkarakayil H, Nampoothiri M, Kachapilly G, Shameem M,
Raghunath P, Anitha Y. Formulation optimization and evaluation of
aceclofenac sustained release dosages form based on Kollidon sustained
release. Asian J Pharm 2013;7(1):8-14.
22. Manjunatha KM, Ramana MV, Satyanarayana D. Design and evaluation
of diclofenac sodium controlled drug delivery systems. Indian J Pharm
Sci 2007;69(3):384-9.
23. Nidhi, Rashid M, Kaur V, Han SS, Sharma S, Mishra N. Microparticles
as controlled drug delivery carrier for the treatment of ulcerative colitis:
A brief review. Saudi Pharm J 2014;Doi: 10.1016/j.jsps.2014.10.001.
24. Chauhan MJ, Patel SA. A concise review on sustained drug delivery
system and its opportunities. Am J Pharm Tech Res 2012;2:227-38.
25. Aulton ME. Aulton’s Pharmaceutics - The Design and Manufacture of
Medicine. 3rd ed. New York: Churchill Livingstone; 2007.
26. Marroum PJ. Bioavailability/Bioequivalence for Oral Controlled
Release Products, Controlled Release Drug Delivery Systems:
Scientific and Regulatory Issues, Fifth International Symposium on
Drug Development, East Brunswick, NJ: May-15-17, 1997.
27. Kumar KP, Bhowmik D, Srivastava S. Sustained release drug delivery
system potential. Pharm Inov 2012;1:48-60.
28. Lee TW, Robinson JR. In: Gennaro AR, editor. Remington: The Science
and Practice of Pharmacy. 20th ed. Baltimore: Lippincott Williams and
Wilkins; 2000. p. 903-29.
29. Scientific and Regulatory Issues. Fifth International Symposium on
Drug Development, East Brunswick, NJ: May 1997. p. 15-7.
30. Banker GS, Rhodes CT. Sustained and controlled drug delivery system.
Modern Pharmaceutics. 4th ed. New York: Marcel Dekker; 2002.
31. Shargel L, Pong SW, Yu AB. Modified release drug products. Applied
Biopharmaceutics & Pharmacokinetics. 5th ed. New York: McGrawHill
Medical; 2004.
32. Bramhamankar DM, Jaiswal SB. Biopharmaceutics and
Pharmacokinetics: Pharmacokinetics. 2
ed. New Delhi: Vallabh
Prakashan; 2009. p. 399-401.
nd
33. Ratilal DA, Gaikwad PD, Bankar VH, Pawar SP. A review on: Sustained
release technology. Int J Res Ayurveda Pharm 2011;2:1701-8.
34. B. K. Bansal, Shakya. V, Rewar. S. A New Trend in Oral Sustained
Release Technology; As J Pharm Res Dev 2014;2:91-5.
35. Robinson JR, Lee VH; Controlled Drug Delivery Fundamentals and
Applications. Revised and expanded. 2
ed. New York: Marcel Dekker;
1987.
nd
36. Khalane L, Alkunte A, Birajdar A. Sustained release drug delivery
system: A concise review. Available from: http://www.pharmatutor.
org/articles/sustained-release-drug-delivery-system-concisereview?page=0,0.
37. Ankit B, Rathore RP, Tanwar YS, Gupta S, Bhaduka G. Oral sustained
release dosage form: An opportunity to prolong the release of drug. Int
J Adv Res Pharm Biosci 2013;3(1):7-14.
38. Isha C, Nimrata S, Rana AC, Surbhi G. Oral sustined release drug
delivery system: An overview. Int Res J Pharm Sci 2012;3:1-13.
Statistics
1914 Views | 13571 Downloads
How to Cite
Karna, S., S. Chaturvedi, V. Agrawal, and M. Alim. “FORMULATION APPROACHES FOR SUSTAINED RELEASE DOSAGE FORMS: A REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, no. 5, Sept. 2015, pp. 34-41, https://innovareacademics.in/journals/index.php/ajpcr/article/view/7185.
Section
Review Article(s)